Patent details

Basic Information

Publication number:

EP3436601

PCT Application Number:

EP2017057752

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP177151248

PCT Publication Number:

WO2017167989

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET

French Title of Invention:

NIVEAU D'EXPRESSION DE LA CYTIDINE DÉSAMINASE DANS UN CANCER EN TANT QUE NOUVELLE CIBLE THÉRAPEUTIQUE

German Title of Invention:

CYTIDINDEAMINASEGENEXPRESSIONSNIVEAU BEI KREBS ALS EIN NEUES THERAPEUTISCHES TARGET

SPC Number:

Dates

Filing date:

31/03/2017

Grant date:

29/03/2023

EP Publication Date:

06/02/2019

PCT Publication Date:

05/10/2017

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

29/03/2023

EP B1 Publication Date:

29/03/2023

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

31/03/2023

Expiration date:

31/03/2037

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

22/03/2023

 

 

Name:

Centre National de la Recherche Scientifique

Address:

3, rue Michel-Ange, 75016 Paris, France (FR)

Name:

Institut Curie

Address:

26, rue d'Ulm, 75248 Paris Cedex 05, France (FR)

Inventor

1

Name:

MAMERI, Hamza

Address:

France (FR)

2

Name:

AMOR-GUERET, Mounira

Address:

France (FR)

Priority

Priority Number:

16305380

Priority Date:

31/03/2016

Priority Country:

European Patent Office (EPO) (EP)

Classification

IPC classification:

C12Q 1/68;

Publication

European Patent Bulletin

Issue number:

202313

Publication date:

29/03/2023

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages